Apotex Inc., Canada’s largest drug manufacturer, has won Health Canada approval to sell a generic form of the blockbuster ...

Health Canada has approved the second generic version of brand-name Ozempic, this one manufactured by Canadian company Apotex ...

Canada's largest Canadian-based global health company, today announced that Health Canada has approved Apo-Semaglutide InjectionTM, a generic equivalent of Ozempic® (semaglutide injection). As the ...

Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a ...

The generic medication was developed through a strategic partnership with Orbicular Pharmaceutical Technologies.

Under the agreement, Apotex will acquire Cumberland's portfolio of branded medicines for cash.

TORONTO, April 23, 2026 /PRNewswire/ - Apotex, the largest Canadian based pharmaceutical company, and Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. based specialty pharmaceutical company, ...

TORONTO, March 30, 2026 /CNW/ - Apotex, the Canadian-based global health company, today announced key changes to its executive leadership structure designed to strengthen its long-term strategic ...

Apotex, in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, today announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated ...

On December 22, 2017, Patillo J. of the Ontario Super Court of Justice held that Apotex was entitled to $11,303,131.80, plus pre-judgment interest, for losses flowing from delays in the US Food and ...

U.S. market will not open until patent expires in 2032, but individual generics can be sold in Canada once approved ...

Many biosimilar applicants have resorted to inter partes review (IPR) proceedings to challenge innovator patents as an alternative forum to district court litigation under the BPCIA. For those ...